Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 1 of 10
International Atomic Energy Agency
Survey...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 2 of 10
A.2 Is your nuclear medicine department o...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 3 of 10
C1.3.2 Total body function Yes Nocamera 3...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 4 of 10
C4.2.2 Crystal type
C4.2.3 Mode of acquis...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 5 of 10
C13.1 Thyroid uptake system 1 Year of Ins...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 6 of 10
D2.3 Radioisotopes for therapy:
D2.3.1 Re...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 7 of 10
F. VOLUME OF NUCLEAR MEDICINE PROCEDURES
...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 8 of 10
F1.9 Pulmonary Procedures
F1.9.1 Lung Per...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 9 of 10
G3.6 Too much regulation upon using radio...
Rev 5 30 Sept 2005
Part 2 Survey for Current Status NM, 2005-11-15, Page 10 of 10
G.9. National Programme & Other Bilatera...
Upcoming SlideShare
Loading in …5
×

Part 2 Survey for Current Status NM

360 views

Published on

Published in: Health & Medicine, Technology
  • Be the first to comment

  • Be the first to like this

Part 2 Survey for Current Status NM

  1. 1. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 1 of 10 International Atomic Energy Agency Survey of the current status of Nuclear Medicine Instructions: The objective of the collection and analysis of the international database concerning the status of nuclear medicine is to maintain an updated information database regarding the status of Nuclear Medicine in Member States. The database will be useful in: (1) understanding of current status of infrastructures and educational systems in implementing nuclear medicine in Member States, (2) assisting in formulating possible approaches to emerging needs that could be come out from the survey, (3) assisting in prioritizing the educational and operational needs related to establish and/or strengthen nuclear medicine in developing countries, and (4) proposing of a role model for effective promotion of NM in developing countries. This Part 2 of the survey should be completed by a representative of each individual Nuclear Medicine Department(s) or Centers operating in your country. TC National Liaison officers and/or Ministry of Health Representatives should distribute and collect this Part 2 form to each active operating Nuclear Medicine Centers that is described in the Part 1, B.2. Please return Part 2 of this form by 31 DECEMBER 2005 to Dr. Maurizio Dondi, NAHU-NM, Wagramerstrasse 5, P.O. Box 100, A-1400, Vienna, Austria by mail, +43-1-26007-21671 by Fax and/or e-mail to nuclearmedicine@iaea.org or j.choe@iaea.org. PART 2. SPECIFIC INFORMATION FROM NUCLEAR MEDICINE CENTER A. INFORMATION ON INDIVIDUAL NUCLEAR MEDICINE CENTER A.1. Please provide contact information of your hospital and department. A1.1 Name of Hospital A1.2 Type of Institution University based Hospital based Private practice Other A1.3.1 Building A1.3.5 ZIP A1.3.2 Street A1.3.6 County/State A1.3.3 PO Box A1.3.7 Country A1.3 Address A1.3.4 City A1.4 Title of Nuclear Medicine Center A1.5 Name of contact person A1.6 Title of the contact person A1.7 Telephone A1.8 Fax A1.9 e-mail
  2. 2. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 2 of 10 A.2 Is your nuclear medicine department operating independently? Yes No A.3. If No, which department is your center affiliated to? Radiology Internal Medicine Clinical Laboratory Radiation Oncology (Radiotherapy) Other A.4. What nuclear medicine services does your department provide? A4.1 In vivo imaging A4.2 In vivo physiologic studies (e.g. Schilling test) A4.3 In vitro studies (RIA, IRMA) A4.4 Radionuclide therapy A4.5 Bone densitometry A4.6 Radiopharmacy procedures (Making reagents by yourself) A4.7 Molecular biology (DNA,RNA, PCR, Molecular imaging, etc.) A4.8 Other B. NUCLEAR MEDICINE DEPARTMENT STAFF B.1. Number of nuclear medicine staff Number B1.1 Number of nuclear medicine physicians B1.2 Number of physician in-training in NM B1.3 Number of nuclear medicine physicists B1.4 Number of nurses B1.5 Number of radiopharmacists B1.6 Number of technologists B1.7 Number of other scientific staff B.2. Does your department provide post-graduate medical education and training in nuclear medicine? Yes No B.2.1. If yes, please explain the program. _____________________________________________ C. EQUIPMENTS AND FACILITIES Please provide information about equipments now operating in your department. Please attach more sheet(s) if you have more equipments. C.1. Planar-only Gamma cameras. C1.0 Total number C1.1.1 Year of Installation C1.1.2 Total body function Yes No C1.1 Planar gamma camera 1 C1.1.3 DICOM Connectivity Yes No C1.2.1 Year of Installation C1.2.2 Total body function Yes No C1.2 Planar gamma camera 2 C1.2.3 DICOM Connectivity Yes No C1.3 Planar gamma C1.3.1 Year of Installation
  3. 3. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 3 of 10 C1.3.2 Total body function Yes Nocamera 3 C1.3.3 DICOM Connectivity Yes No C.2. SPECT Gamma cameras. C2.0 Total number C2.1.1 Year of Installation C2.1.2 Number of Heads (1=single, 2=dual, 3=triple, etc.) C2.1.3 Variable angle geometry (for dual head only) Yes No C2.1.4 Total body function Yes No C2.1.5 Attenuation correction function by external source Yes No C2.1.6 Coincidence function to image positron emitter Yes No C2.1 SPECT Gamma camera 1 C2.1.7 DICOM Connectivity Yes No C2.2.1 Year of Installation C2.2.2 Number of Heads (1=single, 2=dual, 3=triple, etc.) C2.2.3 Variable angle geometry (for dual head only) Yes No C2.2.4 Total body function Yes No C2.2.5 Attenuation correction function by external source Yes No C2.2.6 Coincidence function to image positron emitter Yes No C2.2 SPECT Gamma camera 2 C2.2.7 DICOM Connectivity Yes No C2.3.1 Year of Installation C2.3.2 Number of Heads (1=single, 2=dual, 3=triple, etc.) C2.3.3 Variable angle geometry (for dual head only) Yes No C2.3.4 Total body function Yes No C2.3.5 Attenuation correction function by external source Yes No C2.3.6 Coincidence function to image positron emitter Yes No C2.3 SPECT Gamma camera 3 C2.3.7 DICOM Connectivity Yes No C.3. PET Scanners. C3.0 Total number C3.1.1 Year of Installation C3.1.2 Crystal type C3.1.3 Mode of acquisition 3-D 2-D C3.1.4 Transmission source C3.1 PET Scanner 1 C3.1.5 DICOM Connectivity Yes No C3.2.1 Year of Installation C3.2.2 Crystal type C3.2.3 Mode of acquisition 3-D 2-D C3.2.4 Transmission source C3.2 PET Scanner 2 C3.2.5 DICOM Connectivity Yes No C.4. PET-CT Scanners. C4.0 Total number C4.1.1 Year of Installation C4.1.2 Crystal type C4.1.3 Mode of acquisition 3-D 2-D C4.1.4 Transmission source C4.1.5 Number of Slices of CT C4.1 PET-CT Scanner 1 C4.1.6 DICOM Connectivity Yes No C4.2 PET-CT Scanner 2 C4.2.1 Year of Installation
  4. 4. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 4 of 10 C4.2.2 Crystal type C4.2.3 Mode of acquisition 3-D 2-D C4.2.4 Transmission source C4.2.5 Number of Slices of CT C4.2.6 DICOM Connectivity Yes No C.5. If you do not have PET or PET-CT Scanners, do you have plan to install one in near future (within 3 years)? Yes No C.6. Cyclotrons. C6.0 Total number C6.1.1 Year of Installation C6.1.2 Maximum Energy C6.1 Cyclotron 1 C6.1.3 Type of particle C.7. If you do not have cyclotron, do you have plan to install one in near future (within 3 years)? Yes No C.8. Chemistry module for cyclotron C8.0 Total number C8.1.1 Year of Installation C8.1.2 Make In-house Commercial C8.1 Module 1 C8.1.3 Product C.9. Intraoperative gamma probe C9.0 Total number C9.1 Gamma Probe 1 Year of Installation C9.2 Gamma Probe 2 Year of Installation C.10. Gamma counters C10.0 Total number C10.1 Automatic gamma counter C.11. Beta counters C11.0 Total number C.12. Bone densitometers C12.0 Total number C12.1.1 Year of InstallationC12.1 Bone densitometer 1 C12.1.2 Type Dual energy X-ray Isotope C12.2.1 Year of InstallationC12.2 Bone densitometer 2 C12.2.2 Type Dual energy X-ray Isotope C.13. Thyroid uptake systems C13.0 Total number
  5. 5. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 5 of 10 C13.1 Thyroid uptake system 1 Year of Installation C13.2 Thyroid uptake system 2 Year of Installation C.14. Dose calibrator C14.0 Total number C14.1.1 Year of Installation C14.1.2 Type/Model C14.1 Dose calibrator 1 C14.1.3 Frequency of calibration Semi-annually Annually Every 2 year Infrequent None C14.2.1 Year of Installation C14.2.2 Type/Model C14.2 Dose calibrator 2 C14.2.3 Frequency of calibration Semi-annually Annually Every 2 year Infrequent None C.15. Do you have laminar flow hood in your department? Yes No C.16. Do you have radioiodine safety cabinet (fume hood with filter) in your department? Yes No C.17. Please add additional comments, if any: D. RADIOISOTOPES AND RADIOPHARMACEUTICALS D.1 Please indicate radioisotope generators now using in your department. (You should indicate ‘Local’ if you make the radioisotope or radiopharmaceutical in your department or institution by yourself (not simple reconstitution of cold vial); ‘Commercial’ if you purchase radioisotopes or cold vial from outside vendors, irrespective of domestic or foreign maker; ‘Not use’ if you do not use any of those.) D1.1 Mo-Tc generator Yes ( Local Commercial) Not use D1.2 Other generator system Yes (Please specify ) Not use D.2. Please indicate the Reagents and Radiopharmaceuticals that your department is now using: Radiopharmaceuticals Utilisation D2.1 Radioisotopes for in vivo imaging: D2.1.1 I-131 Yes ( Local Commercial) Not use D2.1.2 I-123 Yes ( Local Commercial) Not use D2.1.3 In-111 Yes ( Local Commercial) Not use D2.1.4 Tl-201 Yes ( Local Commercial) Not use D2.1.5 Ga-67 Yes ( Local Commercial) Not use D2.1.6 Tc-99m Unit Dose Yes ( Local Commercial) Not use D2.1.7 Other (please specify) Yes ( Local Commercial) Not use D2.2 Radioisotopes for in vivo physiological tests D2.2.1 Cr-51 (EDTA) Yes ( Local Commercial) Not use D2.2.2 Co-57 (Vitamin B-12) Yes ( Local Commercial) Not use D2.2.3 C-14 (Urea) Yes ( Local Commercial) Not use D2.2.4 Other (please specify) Yes ( Local Commercial) Not use
  6. 6. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 6 of 10 D2.3 Radioisotopes for therapy: D2.3.1 Re-188 Yes ( Local Commercial) Not use D2.3.2 Ho-166 Yes ( Local Commercial) Not use D2.3.3 I-131 Yes ( Local Commercial) Not use D2.3.4 Sr-89 Yes ( Local Commercial) Not use D2.3.5 Y-90 Yes ( Local Commercial) Not use D2.3.6 Sm-153 Yes ( Local Commercial) Not use D2.3.7 P-32 Yes ( Local Commercial) Not use D2.3.8 Other (please specify) Yes ( Local Commercial) Not use D2.4 In vitro radioisotopes for clinical use D2.4.1 I-125 Yes ( Local Commercial) Not use D2.5 Cold Reagent for Tc-99m labelling; First generation D2.5.1 DTPA Yes ( Local Commercial) Not use D2.5.2 DMSA Yes ( Local Commercial) Not use D2.5.3 MDP Yes ( Local Commercial) Not use D2.5.4 DISIDA/HIDA Yes ( Local Commercial) Not use D2.5.5 Sulphur colloid Yes ( Local Commercial) Not use D2.5.6 Antimony sulphide Yes ( Local Commercial) Not use D2.5.7 Phytate Yes ( Local Commercial) Not use D2.5.8 MAA Yes ( Local Commercial) Not use D2.5.9 Human serum albumin Yes ( Local Commercial) Not use D2.5.10 Other (please specify) Yes ( Local Commercial) Not use D2.6 Other 2nd and 3rd generation labelled compounds D2.6.1 Sestamibi Yes ( Local Commercial) Not use D2.6.2 Tetrofosmin Yes ( Local Commercial) Not use D2.6.3 Teboroxime Yes ( Local Commercial) Not use D2.6.4 ECD Yes ( Local Commercial) Not use D2.6.5 HMPAO Yes ( Local Commercial) Not use D2.6.6 MAG3 Yes ( Local Commercial) Not use D2.6.7 MIBG Yes ( Local Commercial) Not use D2.6.8 Octreotide Yes ( Local Commercial) Not use D2.6.9 Other (please specify) Yes ( Local Commercial) Not use D2.7 PET Radioisotopes D2.7.1 F-18 FDG Yes ( Local Commercial) Not use D2.7.2 F-18 FDOPA Yes ( Local Commercial) Not use D2.7.3 C-11 Methionine Yes ( Local Commercial) Not use D2.7.4 C-11 Choline Yes ( Local Commercial) Not use D2.7.5 N-13 Yes ( Local Commercial) Not use D2.7.6 O-15 Yes ( Local Commercial) Not use D2.7.7 Rb-82 generator Yes ( Local Commercial) Not use D2.7.8 Other (please specify) Yes ( Local Commercial) Not use E. RADIONUCLIDE THERAPY E.1. How many beds does your hospital have for confined radioisotope therapy? ________
  7. 7. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 7 of 10 F. VOLUME OF NUCLEAR MEDICINE PROCEDURES F.1. Please indicate the Studies/Examinations performed in your department and the frequency In vivo Name of study/examination Number of procedures, last year (fiscal year) F1.1.1 Intraoperative Gamma Probe procedures (sentinel node) F1.2 Cardiovascular Procedures F1.2.1 Myocardial Perfusion Imaging F1.2.2 Radionuclide Ventriculography (MUGA) F1.3 Endocrine Procedures F1.3.1 Thyroid Tc-99m Scan F1.3.2 Thyroid I-123 or I-131 Uptake and Scan F1.3.3 Parathyroid F1.3.4 Adrenal Scan (I-131 nor-cholesterol scan; I-123 or I-131MIBG) F1.4 Gastrointestinal Procedures F1.4.1 Esophageal transit study F1.4.2 Gastro-Esophageal reflux study F1.4.3 Gastric Emptying Scan (Liquids and Solids) F1.4.4 Hepatobiliary F1.4.5 Hepatic Hemangioma with SPECT F1.4.6 GI Bleed F1.4.7 Meckel's Diverticulum (Ectopic Gastric Mucosa) F1.4.8 Schillings Test F1.4.9 C-14 Urea breath test for H. pylori F1.5 Genitourinary Procedures F1.5.1 Renal Scan (Renogram) F1.5.2 Renal Scan (Renogram) with Captopril F1.5.3 Renal Scan (Renogram) with Furosemide F1.5.4 Renal Cortical Study (DMSA) F1.5.5 Nuclear Cystogram F1.5.6 Male and Female genital system scans F1.6 Oncology Procedures F1.6.1 Whole body PET scan F1.6.2 Whole body Gallium scan F1.6.3 Whole body In-111 Octreotide scan F1.6.4 (I-131 or I-123) MIBG scan F1.6.5 Whole body Sestamibi/Tl-201 Scan F1.6.6 I-131 Whole body Scan F1.7 Miscellaneous Procedures F1.7.1 Salivary glands Scan F1.7.2 Lymphoscintigraphy (peripheral) F1.7.3 Lymphoscintigraphy for sentinel node F1.7.4 Gallium scan for infections F1.7.5 In-111 or Tc-99m Leukocyte Study (Infection or IBD) F1.8 Nervous System Procedures F1.8.1 Brain Perfusion Scan with SPECT (HMPAO or ECD) F1.8.2 Brain Receptors Scan (DAT-Scan/IBZM) F1.8.3 Brain PET studies F1.8.4 Cisternogram (including V-P shunt evaluation)
  8. 8. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 8 of 10 F1.9 Pulmonary Procedures F1.9.1 Lung Perfusion F1.9.2 Lung Ventilation F1.10 Skeletal Procedures F1.10.1 Bone Scan (whole body) F1.10.2 Bone Marrow Scan F1.11 Therapeutic Procedures F1.11.1 1-131 Therapy, Hyperthyroidism F1.11.2 1-131 Therapy Thyroid Ablation/Metastases F1.11.3 Strontium-89 Therapy, Palliation of Pain From Bony Metastasis F1.11.4 Therapy with I-131 MIBG F1.11.5 Radiosynovectomy F1.11.6 Other F1.12 In vitro techniques Name of procedure Number of procedures , Last year (Fiscal year) F1.12.1 RIA Tumor markers F1.12.2 RIA Hormonal markers F1.12.3 RIA Thyroid markers F1.12.4 RIA Hepatitis F1.12.5 Molecular biology works (DNA, RNA, PCR, etc.) F1.12.6 RIA Others (please specify) F.2. Applications. Please indicate which fields of application are relevant in your work F2.1 Thyroid disorders F2.2 Screening for congenital hypothyroidism F2.3 Oncology SPECT F2.4 Oncology PET F2.5 Infections F2.6 Cardiovascular disease F2.7 Degenerative diseases/Brain F2.8 Receptor imaging F2.9 Therapeutic applications G. PERSPECTIVES OF NUCLEAR MEDICINE AND TRAINING NEEDS G.1. Does your hospital request more active nuclear medicine practice? (1) Very much (2) Much (3) Average (4) Not as much (5) Not at all G.2. Do you think that your department perform effectively to your hospital’s needs? (1) Very much (2) Much (3) Average (4) Not as much (5) Not at all G.3. If you responded on G.2. question as ‘Not as much’ or ‘Not at all’, do think what is the main reason not to perform effectively? (Select 3 most relevant.) G3.1 Insufficient manpower G3.2 Insufficient equipments G3.3 Insufficient radioisotope or radiopharmaceuticals supply G3.4 Insufficient education and training G3.5 Insurance system not to adequately reimburse for the nuclear medicine procedures
  9. 9. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 9 of 10 G3.6 Too much regulation upon using radioisotopes G3.7 Other (Please explain) ______________________________________________________ G.4. Do you think how much volume of nuclear medicine procedures will grow in next 5 years in your hospital? ___________ % G.5. Please indicate which sector(s) needs training through IAEA? Please rate, on a scale of 1 to 5, (1 being the HIGHEST and 5 being the LOWEST) the items below to identify the training priorities in your department (in each row, please mark an X in one of the boxes provided). Personnel 1 2 3 4 5 G5.1 Nuclear medicine Physician. G5.2 Nuclear Medicine Technologists G5.3 Radiochemists/Radiopharmacists G5.4 Nuclear Medicine Physicists G5.5 Nuclear Medicine Nurses G.6. Do you or your staff participate in continuous professional development education or program? Yes No G.7. Training Needs Your input in the section below will allow us to better understand the priority areas regarding your training needs in order to prepare the work plan of activities including regional training courses and workshops in 2005 and 2006. Please rate, on a scale of 1 to 5, (1 being the HIGHEST and 5 being the LOWEST) the topics below to identify the training priorities in your country (in each row, please mark an X in one of the boxes provided). Subject 1 2 3 4 5 G7.1 Thyroid disorders G7.2 Cardiology G7.3 Paediatrics G7.4 Therapeutic nuclear medicine G7.5 Interventional nuclear medicine G7.6 Nephro-urology G7.7 Diagnosis and treatment of oncological disorders G7.8 Clinical applications of SPECT G7.9 Clinical applications of PET G7.10 Infection & inflammation G7.11 Brain diseases G7.12 Receptor imaging G.8. Please feel free to provide any additional information below relevant to your training needs and/or cooperation with the IAEA:
  10. 10. Rev 5 30 Sept 2005 Part 2 Survey for Current Status NM, 2005-11-15, Page 10 of 10 G.9. National Programme & Other Bilateral Assistance: Please provide information on which ongoing national programme or strategy addresses the topic of nuclear medicine, cardiology and/or cancer management in general in your country. Please also provide information on any other assistance that is being received from international sources (i.e. WHO, NGO’s, bilateral donors) Please kindly return the completed form to Dr. Maurizio Dondi, NAHU-NM, Wagramerstrasse 5, P.O. Box 100, A-1400, Vienna, Austria by mail, +43-1-26007-21671 by Fax and/or e-mail to nuclearmedicine@iaea.org or j.choe@iaea.org by 31 DECEMBER 2005. We welcome your feedback and thank you for your time in completing this survey! If you have any questions and comments please feel free to contact Dr. Jae-Gol Choe (j.choe@iaea.org) at +43-1-2600-21655 or Dr. Maurizio Dondi, Head, Section of Nuclear Medicine (m.dondi@iaea.org)

×